
Accepted Manuscript

Continuation of long-acting reversible contraceptives among Medicaid patients



PII: S0010-7824(18)30148-3

DOI: doi:10.1016/j.contraception.2018.04.012

Reference: CON 9094

To appear in:

Received date: 8 January 2018 Revised date: 12 April 2018 Accepted date: 18 April 2018

Please cite this article as: Max J. Romano, Patryce Toye, Loral Patchen, Continuation of long-acting reversible contraceptives among Medicaid patients. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Con(2018), doi:10.1016/j.contraception.2018.04.012

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: Continuation of long-acting reversible contraceptives among Medicaid patients

Authors:

- 1. Dr. Max J. Romano, MD, MPH^{a,b}
- a. MedStar Franklin Square Medical Center Family Medicine Residency Program
- b. Johns Hopkins Bloomberg School of Public Health General Preventive Medicine Residency Program

Present Address: see corresponding author address below

- 2. Dr. Patryce Toye, MD^c c. MedStar Family Choice 5233 King Ave, Ste. 400 Rosedale, MD 21237 Patryce.Toye@medstar.net
- 3. Dr. Loral Patchen, PhD, CNM^{d,e}
- d. MedStar Health Research Institute
- e. MedStar Washington Hospital Center

110 Irving St. NW Suite EB-7113

Washington, DC 20010

Loral.Patchen@medstar.net

Conflicts of interest: Drs. Romano and Patchen have received free CME trainings and certification on insertion of all of the long-acting contraceptive devices discussed in this presentation, which were sponsored by the manufacturers Merck & Co., Bayer AG, and Teva Pharmaceutical Industries. The authors report no other conflicts of interest. Dr. Patchen also discloses participation in the Diclegis speakers bureau.

Support: This work was financially supported by MedStar Family Choice, a Medicaid managed-care organization operating in Maryland and Washington, DC. The funder supplied insurance claims data for the project and provided oversight for the analysis, interpretation, and writing of the final manuscript.

Presentations: This work was presented at the MedStar Health Research Institute 6th Annual Research Symposium in Bethesda, MD, on May 1, 2017.

Corresponding Author:

Max J. Romano Mromano4@jhu.edu General Preventive Medicine Residency Program 615 N. Wolfe St., WB602 Baltimore, MD 21205 Phone: 410-955-3630

Abstract Word Count: 240 Main Text Word Count: 2,373

Download English Version:

https://daneshyari.com/en/article/8777375

Download Persian Version:

https://daneshyari.com/article/8777375

<u>Daneshyari.com</u>